Search

Displaying results 2591 - 2600 of 10000 in total
  1. Drug

    Alcaftadine

    go.drugbank.com/drugs/DB06766
    Approved

    This drug was approved in July 2010.

  2. Drug

    Gallium Ga-68 gozetotide

    go.drugbank.com/drugs/DB16019
    ApprovedInvestigational

    [L27006] On December 1, 2020, Ga-68 PSMA-11 was approved by the FDA as the first molecular-targeted drug for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA) … positive lesions in men with prostate cancer.

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    Sipavibart

    go.drugbank.com/drugs/DB21908
    ApprovedInvestigational

    [L53418] Sipavibart gained its first global approval in Japan in December 2024.[A274088] It was later approved in Europe in January 2025 and in Canada in March 2025. … [A274088] Sipavibart is approved for the pre-exposure prophylaxis treatment of COVID-19 in immunocompromised patients.[L53418]

    Synonyms: Immunoglobulin G1 [242-phenylalanine,243-glutamic acid,260-tyrosine,262-threonine,264-glutamic acid,339-serine], anti-(severe acute respiratory syndrome coronavirus 2 spike glycoprotein receptor-binding
  4. Drug

    Fostemsavir

    go.drugbank.com/drugs/DB11796
    ApprovedInvestigational

    [A215057] Fostemavir is the first attachment inhibitor to receive FDA approval, granted in July 2020 for use in combination with other antiretrovirals in highly treatment-experienced patients with multidrug-resistant … prevents the first step in the HIV-1 viral lifecycle.

  5. Drug

    Bromotheophylline

    go.drugbank.com/drugs/DB14018
    Approved

    [A33018] Bromotheophylline is categorized on the FDA as a drug substance with an inactive state since March, 1980. … [L1082] It is also approved by Health Canada to be used alone or in combination with [DB00316] in OTC products.[L1113]

    Mixtures: PAMACET 500 MG/25 MG/15 MG FİLM KAPLI TABLET, 24 ADET, PAMACET 500 MG/25 MG/15 MG FİLM KAPLI TABLET, 40 ADET
  6. Drug

    Remestemcel-L

    go.drugbank.com/drugs/DB13973
    ApprovedInvestigationalWithdrawn

    with first-line therapies, putting them in a risk for poor outcomes and creating a significant clinical challenge [A31818]. … Based on its tolerability and safety profile, remestemcel-L is a promising alternative to second-line immunosuppressive agents [A31818].

  7. Drug

    Berotralstat

    go.drugbank.com/drugs/DB15982
    ApprovedInvestigational

    [A225106] Berotralstat was first approved by the FDA on December 3, 2020, as the first once-daily oral therapy to prevent angioedema attacks of HAE in adults and pediatric patients 12 years and older. … [L41960] In December 2025, the FDA expanded Berotralstat pediatric use with approval of an oral pellet formulation for prophylaxis in children with HAE aged 2 and older.[L54793,L54798]

    Synonyms: 2-[3-(aminomethyl)phenyl]-N-[5-[(R)-(3-cyanophenyl)-(cyclopropylmethylamino)methyl]-2-fluorophenyl]-5-(trifluoromethyl)pyrazole-3-carboxamide, (+)-1-(3-(aminomethyl) phenyl)-N-(5-((3-cyanophenyl)(cyclopropylmethylamino)methyl)-2-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide dihydrochlorideCategories: Drugs Used in Hereditary Angioedema
  8. Drug

    Bazedoxifene

    go.drugbank.com/drugs/DB06401
    ApprovedInvestigational

    It is approved in the European Union (marketed in Italy and Spain) and Japan as monotherapy. … the prevention of postmenopausal osteoporosis in women.

    Mixtures: DUAVIVE 20 mg/0.45 mg modified - release tablets, DUAVİVE 0.45 MG/20 MG DEĞİŞTİRİLMİŞ SALIMLI TABLET, 30 TABLET
  9. Drug

    Abarelix

    go.drugbank.com/drugs/DB00106
    ApprovedWithdrawn

    Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market.

  10. Drug

    V1003

    go.drugbank.com/drugs/DB05046
    Experimental

    V1003 is an intranasal formulation of buprenorphine, an opiate analgesic, for the management of post-operative pain in hospital and home settings.